A carregar...
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials. In 2 recent communications that focused on short-term and long-term ruxolitinib treatment outcome, respectively, the drug was shown to be eff...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mayo Foundation for Medical Education and Research
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228619/ https://ncbi.nlm.nih.gov/pubmed/22034658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4065/mcp.2011.0518 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|